Stock IPSC CENTURY THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Century Therapeutics, Inc.

Equities

IPSC

US15673T1007

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-10 pm EDT 		5-day change 1st Jan Change
3.35 USD +13.95% Intraday chart for Century Therapeutics, Inc. +12.42% +0.90%
Jun. 03 Century Therapeutics Presents Interim Results from Phase 1 Elipse-1 Study At Asco 2024 Annual Meeting CI
May. 10 Century Therapeutics Presents Preclinical Data Highlighting Advances in Ipsc Platform Technology and Programs At 2024 Asgct Annual Meeting CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Century Therapeutics Presents Interim Results from Phase 1 Elipse-1 Study At Asco 2024 Annual Meeting
CI
Century Therapeutics Presents Preclinical Data Highlighting Advances in Ipsc Platform Technology and Programs At 2024 Asgct Annual Meeting
CI
Century Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Syncona agrees to sell stake in investee company for GBP7.4 million
AN
Syncona to Sell Stake in Portfolio Company to Century Therapeutics
MT
Century Therapeutics Announces Plans to Expand Clinical Development for Its Lead Program, CNTY-101
CI
Century Therapeutics, Inc. acquired Clade Therapeutics, Inc. from Syncona Limited for $45 million..
CI
Century Therapeutics, Inc. agreed to acquire Clade Therapeutics, Inc. from Syncona Limited for $45 million.
CI
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research Annual Meeting
CI
Century Therapeutics Shares Fall After Wider Loss, Lower Revenue in 2023
MT
Century Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for A Multi-Dosing Strategy for Car iNK Enabled by Allo-Evasion Edits
CI
Century Therapeutics Gets FDA Clearance for Phase 1 Trial of Potential Systemic Lupus Therapy
MT
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
CI
Century Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Century Therapeutics, Inc. and FUJIFILM Cellular Dynamics Enter into a Worldwide License Agreement
CI
Earnings Flash (IPSC) CENTURY THERAPEUTICS Reports Q2 Revenue $99,000
MT
Century Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Earnings Flash (IPSC) CENTURY THERAPEUTICS Reports Q1 Revenue $1.7M
MT
Century Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IPSC Stock
  4. News Century Therapeutics, Inc.
  5. Highlights